Ligand Pharmaceuticals Incorporated
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) with its license and related supply agreements with Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) for drug formulation with ganaxolone. Under the agreement, Ligand will receive an upfront payment and is entitled to receive potential milestone payments, royalties and revenue from future sales of Captisol-enabled ganaxolone.
Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Marinus Pharmaceuticals is a biopharmaceutical company that develops ganaxolone to help improve the lives of patients that suffer from epilepsy and neuropsychiatric disorders. Read the press release.
San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.